IP Library › Granted Patent US 12,416,009
Granted Patent B2
US 12,416,009 · App. 17/270,134 · Granted Sep 16, 2025

Methods and compositions for the modification of plants

Inventors: Maria Helena Christine Van Rooijen (Cambridge, MA); Hok Hei Tam (Newton, MA); Maier Steve Avendaño Amado (Cambridge, MA); Barry Andrew Martin (Boston, MA); Ignacio Martinez (Lexington, MA); Piotr Stanislaw Kowalski (Cork, IE); Nataliya Vladimirovna Nukolova (Cambridge, MA); Yajie Niu (Lexington, MA)
Assignee: Flagship Pioneering Innovations VI, LLC
C12N15/8213C12N15/827
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,416,009
App. No.
17/270,134
Filed
Feb 22, 2021
Granted
Sep 16, 2025
Kind
B2
Art Unit
1663
USPC
800/290
Abstract

Disclosed herein are plant-modifying compositions including a plurality of plant messenger packs (PMPs) (e.g., including a plant extracellular vesicle (EV), or segment, portion, or extract thereof), wherein the PMPs include a plant-modifying agent, and wherein the plant-modifying agent comprising the heterologous RNA. The compositions herein are useful in methods for modifying plants such as to increase plant fitness, wherein the increase in plant fitness comprising an increase in development, growth, yield, resistance to abiotic stressors, or resistance to biotic stressors.

Claims (11)

1. A method of administering at least one heterologous RNA to an intact plant, the method comprising non-viral delivery to the intact plant of a composition comprising a plurality of lipid-reconstituted plant messenger packs (LPMPs), each of the plurality comprising the at least one heterologous RNA, an exogenous cationic lipid, and at least one plant protein extracellular vesicle marker, wherein the exogenous cationic lipid increases the RNA loading efficiency as compared to the loading efficiency of an LPMP not comprising the at least one heterologous cationic lipid, and wherein the composition is delivered at an effective concentration to increase plant fitness.

2. The method of claim 1 , wherein the at least one heterologous RNA is a guide RNA (gRNA).

3. The method of claim 2 , wherein the gRNA is a component of a ribonucleoprotein complex (RNP), and wherein each of the plurality of LPMPs comprise the RNP.

4. The method of claim 1 , wherein the exogenous cationic lipid is DC-Cholesterol or DOTAP.

5. The method of claim 1 , wherein the at least one heterologous RNA is encapsulated by the LPMPs.

6. The method of claim 1 , wherein the LPMPs in the composition are at a concentration effective to modify a plant trait, wherein the modification increases the fitness of the plant.

7. The method of claim 1 , wherein the increase in plant fitness is an increase in development, growth, yield, resistance to abiotic stressors, or resistance to biotic stressors.

8. The method of claim 1 , wherein the increase in plant fitness is a modification to flowering time.

9. The method of claim 4 , wherein the DC-cholesterol comprises between 20-40% of total lipids in the LPMP by weight.

10. The method of claim 4 , wherein the DOTAP comprises between 25-40% of total lipids in the LPMP by weight.

11. The method of claim 1 , wherein the at least one heterologous RNA is siRNA or tracrRNA.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2021
From: VAN ROOIJEN, MARIA HELENA CHRISTINE; TAM, HOK HEI; AVENDANO AMADO, MAIER STEVE; MARTIN, BARRY ANDREW; MARTINEZ, IGNACIO
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 057641/0130 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2021
From: NUKOLOVA, NATALIYA VLADIMIROVNA; KOWALSKI, PIOTR STANISLAW
To: VL52, INC.
Reel/Frame 057641/0495 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2021
From: NIU, YAJIE
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 057641/0851 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2021
From: VL52, INC.
To: FLAGSHIP PIONEERING, INC.
Reel/Frame 057641/0962 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2021
From: FLAGSHIP PIONEERING, INC.
To: FLAGSHIP PIONEERING INNOVATIONS VI, LLC
Reel/Frame 057642/0041 →
Continuity (3)
Provisional Application 62848470 · May 15, 2019
Provisional Application 62722694 · Aug 24, 2018
Related Publication 20210254085A1 · Aug 19, 2021
References Cited (64)
US 9988634B2 · Sammons · 2018 [cited by examiner]
US 10799457B2 · Zhang · 2020 [cited by applicant]
US 11827897B2 · Van Rooijen et al. · 2023 [cited by applicant]
US 12163142B2 · Van Rooijen et al. · 2024 [cited by applicant]
US 20140057789A1 · Sammons · 2014 [cited by examiner]
US 20140308212A1 · Zhang · 2014 [cited by applicant]
US 20160208243A1 · Zhang · 2016 [cited by examiner]
US 20180362974A1 · Zhang · 2018 [cited by applicant]
US 20190380962A1 · Zhang · 2019 [cited by applicant]
US 20210180081A1 · Van Rooijen et al. · 2021 [cited by applicant]
US 20210196632A1 · Van Rooijen et al. · 2021 [cited by applicant]
US 20210219550A1 · Van Rooijen et al. · 2021 [cited by applicant]
US 20210228736A1 · Van Rooijen et al. · 2021 [cited by applicant]
US 20220064661A1 · Van Rooijen et al. · 2022 [cited by applicant]
US 20220152139A1 · Van Rooijen et al. · 2022 [cited by applicant]
US 20220192201A1 · Van Rooijen et al. · 2022 [cited by applicant]
US 20220273565A1 · Van Rooijen et al. · 2022 [cited by applicant]
US 20220288150A1 · Van Rooijen et al. · 2022 [cited by applicant]
US 20220304930A1 · Van Rooijen et al. · 2022 [cited by applicant]
US 20230248649A1 · Zhang · 2023 [cited by applicant]
US 20230355525A1 · Zhang · 2023 [cited by applicant]
US 20240141370A1 · Van Rooijen et al. · 2024 [cited by applicant]
US 20240298649A1 · Bogorad et al. · 2024 [cited by applicant]
US 20240398884A1 · Van Rooijen et al. · 2024 [cited by applicant]
CN 110402085A · 2019 [cited by applicant]
EP 3836779A1 · 2021 [cited by applicant]
JP 2018518183A · 2018 [cited by applicant]
JP 2018522546A · 2018 [cited by applicant]
WO WO2011097480A1 · 2011 [cited by applicant]
WO WO2016205613A1 · 2016 [cited by applicant]
WO WO2016205711A1 · 2016 [cited by applicant]
WO WO2017004526A1 · 2017 [cited by applicant]
WO WO2017004523A1 · 2017 [cited by applicant]
WO WO2017153993A1 · 2017 [cited by applicant]
WO WO2017189308A1 · 2017 [cited by applicant]
WO WO2018005873A1 · 2018 [cited by applicant]
WO WO2018106847A1 · 2018 [cited by applicant]
WO WO2019222379A1 · 2019 [cited by applicant]
WO WO2019222390A1 · 2019 [cited by applicant]
WO WO2020041783A1 · 2020 [cited by applicant]
WO WO2020041784A1 · 2020 [cited by applicant]
WO WO2020214542A1 · 2020 [cited by applicant]
WO WO2020219927A1 · 2020 [cited by applicant]
WO WO2021041301A1 · 2021 [cited by applicant]
WO WO2022266096A1 · 2022 [cited by applicant]
Wang et al 1992 (Journal of Phytopathology 135: p. 233-244) (Year: 1992). [cited by examiner]
Chen et al 2018 (Cancer Metastasis Rev. 37:1, p. 107-124) (Year: 2018). [cited by examiner]
Zhang et al 2010 (International Journal of Pharmaceutics 390: p. 198-207) (Year: 2010). [cited by examiner]
Du et al 2014 (Scientific Reports 4: p. 7107-7113) (Year: 2014). [cited by examiner]
Matthews et al 1981 (Planta 153: p. 90-94) (Year: 1981). [cited by examiner]
Wang et al 2013 (Nature Communications 4:1867 p. 1-11) (Year: 2013). [cited by examiner]
Buckhout et al., “Iron-Stress Induced Redox Activity in Tomato ( [cited by applicant]
Holden et al., “Fe-Chelate Reductase Activity of Plasma Membranes Isolated from Tomato [cited by applicant]
Rutter et al., “Extracellular Vesicles Isolated from the Leaf Apoplast Carry Stress-Response Proteins,” Plant Physiol. 173(1):728-741 (2017). [cited by applicant]
García-Manrique et al., “Therapeutic biomaterials based on extracellular vesicles: classification of bio-engineering and mimetic preparation routes,” J Extracell Vesicles. 7(1):1422676 (2018) (19 pages). [cited by applicant]
International Preliminary Report on Patentability for International Patent Application No. PCT/US2019/048045 issued Mar. 2, 2021 (8 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/048045, mailed Jan. 15, 2020 (22 pages). [cited by applicant]
Invitation to Pay Additional Fees for International Application No. PCT/US2019/048045, mailed Nov. 6, 2019 (3 pages). [cited by applicant]
Luan et al., “Engineering Exosomes as Refined Biological Nanoplatforms for Drug Delivery,” Acta Pharmacol Sin. 38(6):754-63 (2017). [cited by applicant]
Samuel et al., “Extracellular Vesicles Including Exosomes in Cross Kingdom Regulation: A Viewpoint From Plant-Fungal Interactions,” Front Plant Sci. 6:766 (2015) (5 pages). [cited by applicant]
Zhang et al., “Exosome-Mediated Small RNA Delivery: A Novel Therapeutic Approach for Inflammatory Lung Responses,” Mol Ther. 26(9):2119-2130 (2018). [cited by applicant]
Sato et al., “Engineering hybrid exosomes by membrane fusion with liposomes,” Sci Rep. 6:21933 (2016) (11 pages). [cited by applicant]
Wang et al., “Delivery of therapeutic agents by nanoparticles made of grapefruit-derived lipids,” Nature Communications, 4(1867) (May 2013) (14 pages). [cited by applicant]
“Advances in mechanism and application for plant microRNA in cross-kingdom regulation,” ScienceChina. Abstract 06, published Apr. 24, 2020 (2 pages). [cited by applicant]